JP2012530141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012530141A5 JP2012530141A5 JP2012516197A JP2012516197A JP2012530141A5 JP 2012530141 A5 JP2012530141 A5 JP 2012530141A5 JP 2012516197 A JP2012516197 A JP 2012516197A JP 2012516197 A JP2012516197 A JP 2012516197A JP 2012530141 A5 JP2012530141 A5 JP 2012530141A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- apixaban
- released
- controlled release
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 22
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims 13
- 229960003886 apixaban Drugs 0.000 claims 13
- 238000013270 controlled release Methods 0.000 claims 9
- 239000006185 dispersion Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 3
- 230000003204 osmotic effect Effects 0.000 claims 3
- 238000010922 spray-dried dispersion Methods 0.000 claims 3
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000203 mixture Chemical group 0.000 claims 2
- 229920000642 polymer Chemical group 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 206010014522 Embolism venous Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 208000004043 venous thromboembolism Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18744209P | 2009-06-16 | 2009-06-16 | |
| US61/187,442 | 2009-06-16 | ||
| PCT/US2010/038660 WO2010147978A1 (en) | 2009-06-16 | 2010-06-15 | Dosage forms of apixaban |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012530141A JP2012530141A (ja) | 2012-11-29 |
| JP2012530141A5 true JP2012530141A5 (cg-RX-API-DMAC7.html) | 2013-08-01 |
| JP5775071B2 JP5775071B2 (ja) | 2015-09-09 |
Family
ID=42677548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012516197A Active JP5775071B2 (ja) | 2009-06-16 | 2010-06-15 | アピキサバンの製剤形 |
Country Status (24)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160042A1 (es) | 2010-02-25 | 2016-01-28 | Bristol Myers Squibb Holdings Ireland | Formulaciones de apixaban |
| EP2694040A4 (en) * | 2011-03-25 | 2014-09-03 | Selecta Biosciences Inc | SYNTHETIC NANOTRACKERS WITH OSMOTICALLY MEDIATED RELEASE |
| EP2554159A1 (en) | 2011-08-04 | 2013-02-06 | ratiopharm GmbH | Dosage forms comprising apixaban and content uniformity enhancer |
| US20150018386A1 (en) * | 2012-03-06 | 2015-01-15 | Cadila Healthcare Limited | Amorphous form of apixaban, process of preparation and compositions thereof |
| US20150079136A1 (en) * | 2012-04-10 | 2015-03-19 | Rubicon Research Private Limited | Controlled release pharmaceutical formulations of direct thrombin inhibitors |
| EP2854759B1 (en) | 2012-05-24 | 2019-12-18 | ratiopharm GmbH | Dosage forms comprising apixaban and matrix former |
| US8313774B1 (en) | 2012-06-26 | 2012-11-20 | Magnifica Inc. | Oral solid composition |
| EP2900217A1 (en) | 2012-09-26 | 2015-08-05 | Bristol-Myers Squibb Company | Apixaban liquid formulations |
| CN104721156B (zh) * | 2013-12-18 | 2020-05-01 | 山东新时代药业有限公司 | 一种含利伐沙班的片剂 |
| KR20160098508A (ko) * | 2013-12-23 | 2016-08-18 | 라보라토리오스 델 드라. 에스테브.에스.에이. | 경구용 약학 조성물 |
| EP2907507A1 (en) * | 2014-02-17 | 2015-08-19 | Sandoz Ag | Pharmaceutical composition comprising apixaban |
| CN104971355B (zh) * | 2014-04-02 | 2018-04-24 | 上海现代药物制剂工程研究中心有限公司 | 含有利伐沙班的组合物及其制备方法 |
| US20150335586A1 (en) | 2014-05-20 | 2015-11-26 | R.P. Scherer Technologies, Llc | Capsule dispensing container |
| JP6359390B2 (ja) * | 2014-09-05 | 2018-07-18 | テルモ株式会社 | インプラントデバイスおよびインプラントデバイス植え込み具 |
| EP3380083A1 (en) | 2015-11-26 | 2018-10-03 | Zentiva, K.S. | Preparation of a drug form containing amorphous apixaban |
| CN106902115A (zh) * | 2015-12-22 | 2017-06-30 | 江苏万邦生化医药股份有限公司 | 阿哌沙班在治疗糖尿病足药物中的应用 |
| CN108472261B (zh) | 2016-01-12 | 2021-12-03 | 广东东阳光药业有限公司 | 阿哌沙班固体组合物及其制备方法 |
| CN106986868B (zh) * | 2016-01-21 | 2020-04-21 | 广东东阳光药业有限公司 | 包含阿哌沙班的共晶体及其制备方法 |
| US11154558B2 (en) * | 2016-04-15 | 2021-10-26 | Adams Pharmaceuticals LLC | Prevention of atherosclerotic events with direct factor Xa inhibitors |
| WO2017221209A1 (en) | 2016-06-23 | 2017-12-28 | Lupin Limited | Pharmaceutical formulations of apixaban |
| CN108236604A (zh) * | 2018-02-07 | 2018-07-03 | 中国药科大学 | 阿哌沙班柔性脂质体 |
| AU2019226030B2 (en) * | 2018-02-21 | 2025-02-20 | Aron H. BLAESI | Expanding structured dosage form |
| SI3781132T1 (sl) | 2018-04-16 | 2024-07-31 | Bristol-Myers Squibb Company | Formulacije apiksabana |
| KR20190130411A (ko) | 2018-05-14 | 2019-11-22 | 신일제약주식회사 | 아픽사반 약제학적 제제 및 그의 제조방법 |
| WO2020034989A1 (zh) | 2018-08-14 | 2020-02-20 | 江苏恒瑞医药股份有限公司 | 一种可注射的药物组合物及其制备方法 |
| CN109010273B (zh) * | 2018-10-08 | 2021-03-19 | 中国药科大学 | 一种阿哌沙班纳米混悬剂及其制备方法 |
| KR102045721B1 (ko) * | 2019-03-27 | 2019-11-18 | 주식회사 씨트리 | 아픽사반 함유 미립구 제조용 분산상의 조성물 및 이로부터 제조되는 생체적합성 고분자 기반 아픽사반 함유 미립구 |
| KR102044676B1 (ko) * | 2019-03-27 | 2019-11-14 | 주식회사 씨트리 | 생체적합성 고분자 기반 아픽사반 함유 미립구의 제조방법 |
| CN110037990B (zh) * | 2019-04-15 | 2023-03-28 | 海正药业(杭州)有限公司 | 一种阿哌沙班固体无定形分散体的制备工艺 |
| WO2020219384A1 (en) * | 2019-04-26 | 2020-10-29 | Taho Pharmaceuticals Ltd. | Apixaban transdermal delivery system and uses thereof |
| CN114025746B (zh) * | 2019-05-10 | 2023-08-25 | 福多兹制药公司 | 抗血栓形成剂的可注射聚合物纳米颗粒组合物及其方法 |
| JP7752487B2 (ja) * | 2020-03-24 | 2025-10-10 | 日本ジェネリック株式会社 | アピキサバン含有固体分散体 |
| JP7520351B2 (ja) * | 2020-08-14 | 2024-07-23 | 日医工株式会社 | アピキサバン含有医薬組成物 |
| BR112023004824A2 (pt) * | 2020-09-18 | 2023-04-18 | Bristol Myers Squibb Co | Formas de dosagem para inibidores tyk2 compreendendo núcleos intumescíveis |
| EP4259098A1 (en) * | 2020-12-13 | 2023-10-18 | Dafechem Ltd | Liquid apixaban formulation in small dose volume |
| WO2022260943A1 (en) * | 2021-06-08 | 2022-12-15 | Taho Pharmaceuticals Ltd. | Apixaban film product and uses thereof |
| CN115715770B (zh) * | 2021-08-24 | 2024-01-26 | 新领医药技术(深圳)有限公司 | 阿哌沙班透皮贴剂及其制备方法 |
| US12213972B2 (en) * | 2022-07-27 | 2025-02-04 | Slayback Pharma Llc | Stable pharmaceutical compositions of apixaban |
| KR20240102908A (ko) * | 2022-12-26 | 2024-07-03 | 주식회사 렉스팜텍 | 아픽사반을 포함하는 서방성 정제 |
| TW202506133A (zh) * | 2023-04-18 | 2025-02-16 | 美商英賽克利克斯生物有限責任公司 | 投與inx-315之有利人體劑量方案 |
| WO2024261686A1 (en) * | 2023-06-23 | 2024-12-26 | Ronak Patel | A gastroretentive composition comprising apixaban |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4247498A (en) | 1976-08-30 | 1981-01-27 | Akzona Incorporated | Methods for making microporous products |
| US4564488A (en) | 1978-07-31 | 1986-01-14 | Akzo Nv | Methods for the preparation of porous fibers and membranes |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| US4490431A (en) | 1982-11-03 | 1984-12-25 | Akzona Incorporated | 0.1 Micron rated polypropylene membrane and method for its preparation |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| US5225192A (en) | 1988-10-17 | 1993-07-06 | Vectorpharma International S.P.A. | Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| EP0192963B1 (de) | 1985-02-27 | 1988-07-20 | Werkzeugmaschinenfabrik Oerlikon-Bührle AG | Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| WO1992018106A1 (fr) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Procede de production d'une dispersion solide |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| DE4327063A1 (de) | 1993-08-12 | 1995-02-16 | Kirsten Dr Westesen | Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften |
| US6054136A (en) | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| SI9500173B (sl) | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
| US5654005A (en) | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US5686133A (en) | 1996-01-31 | 1997-11-11 | Port Systems, L.L.C. | Water soluble pharmaceutical coating and method for producing coated pharmaceuticals |
| US5993858A (en) | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6492991B1 (en) | 1998-08-28 | 2002-12-10 | Ati International Srl | Method and apparatus for controlling compressed Z information in a video graphics system |
| NZ508118A (en) | 1998-07-06 | 2003-07-25 | Bristol Myers Squibb Co | Heteroaryl substituted biphenyl sulfonamides useful as dual angiotensin endothelin receptor antogonists |
| NZ512410A (en) | 1998-12-17 | 2003-02-28 | Alza Corp | Controlled release liquid filled gelatin capsules comprising barrier, expandable and superpermeable layers and an orifice |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| DE60042352D1 (de) * | 1999-02-10 | 2009-07-23 | Pfizer Prod Inc | Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten |
| ES2310164T3 (es) | 1999-02-10 | 2009-01-01 | Pfizer Products Inc. | Dispositivo de liberacion controlada por la matriz. |
| US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| KR100558239B1 (ko) | 1999-12-23 | 2006-03-10 | 화이자 프로덕츠 인크. | 증가된 약물 농도를 제공하는 제약학적 조성물 |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| CZ20033341A3 (cs) | 2001-06-21 | 2004-10-13 | Pfizeráproductsáinc | Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru |
| MXPA03011922A (es) * | 2001-06-22 | 2004-03-26 | Pfizer Prod Inc | Composiciones farmaceuticas que contienen un dispersion solida de un farmaco ligeramente soluble en una matriz y plimero mejorador de solubilidad. |
| EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| CA2448825C (en) | 2001-06-22 | 2009-08-11 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drug |
| TWI320039B (en) | 2001-09-21 | 2010-02-01 | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | |
| AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| EP1474144B1 (en) * | 2002-02-01 | 2008-08-06 | Pfizer Products Inc. | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
| US20030175346A1 (en) | 2002-02-01 | 2003-09-18 | Anne Billotte | Osmotic delivery system |
| IL162819A0 (en) | 2002-02-01 | 2005-11-20 | Pfizer Prod Inc | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| RU2006102981A (ru) | 2003-08-04 | 2007-09-20 | Пфайзер Продактс Инк. (Us) | Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы |
| GB0417132D0 (en) | 2004-07-31 | 2004-09-01 | Koninkl Philips Electronics Nv | A shift register circuit |
| US7396932B2 (en) | 2004-09-28 | 2008-07-08 | Bristol-Myers Squibb Company | Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| US20060069085A1 (en) | 2004-09-28 | 2006-03-30 | Rulin Zhao | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
| US20070191306A1 (en) * | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
| CN101340933A (zh) * | 2005-08-17 | 2009-01-07 | 百时美施贵宝公司 | 具有环糊精的因子xa抑制剂包合配合物 |
| US20070259913A1 (en) * | 2006-05-04 | 2007-11-08 | David Deitchman | Prophylaxis of thromboembolic events in cancer patients |
| AU2007296311A1 (en) * | 2006-09-12 | 2008-03-20 | Glaxo Group Limited | Pharmaceutical composition comprising a plurality of mini-tablets comprising a Factor Xa inhibitor |
| WO2008066102A1 (en) | 2006-11-30 | 2008-06-05 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
-
2010
- 2010-06-14 SM SM20200093T patent/SMT202000093T1/it unknown
- 2010-06-15 SG SG2011091519A patent/SG176785A1/en unknown
- 2010-06-15 CA CA2765413A patent/CA2765413A1/en not_active Abandoned
- 2010-06-15 WO PCT/US2010/038660 patent/WO2010147978A1/en not_active Ceased
- 2010-06-15 MX MX2011013080A patent/MX2011013080A/es not_active Application Discontinuation
- 2010-06-15 RU RU2012101214/15A patent/RU2012101214A/ru unknown
- 2010-06-15 BR BRPI1010739A patent/BRPI1010739A2/pt not_active Application Discontinuation
- 2010-06-15 HU HUE10727611A patent/HUE048542T2/hu unknown
- 2010-06-15 KR KR1020117030021A patent/KR20120029428A/ko not_active Withdrawn
- 2010-06-15 ES ES10727611T patent/ES2769357T3/es active Active
- 2010-06-15 US US13/378,236 patent/US20120087978A1/en not_active Abandoned
- 2010-06-15 PT PT107276115T patent/PT2442791T/pt unknown
- 2010-06-15 EP EP19158695.7A patent/EP3520776A1/en active Pending
- 2010-06-15 PL PL10727611T patent/PL2442791T3/pl unknown
- 2010-06-15 LT LTEP10727611.5T patent/LT2442791T/lt unknown
- 2010-06-15 EP EP10727611.5A patent/EP2442791B1/en active Active
- 2010-06-15 SI SI201031972T patent/SI2442791T1/sl unknown
- 2010-06-15 CN CN2010800362888A patent/CN102802608A/zh active Pending
- 2010-06-15 DK DK10727611.5T patent/DK2442791T3/da active
- 2010-06-15 HR HRP20200297TT patent/HRP20200297T1/hr unknown
- 2010-06-15 JP JP2012516197A patent/JP5775071B2/ja active Active
- 2010-06-15 AU AU2010260208A patent/AU2010260208B2/en active Active
-
2011
- 2011-11-17 IL IL216421A patent/IL216421A0/en unknown
- 2011-12-19 ZA ZA2011/09334A patent/ZA201109334B/en unknown
-
2013
- 2013-07-02 US US13/933,718 patent/US20140030330A1/en not_active Abandoned
-
2014
- 2014-05-19 US US14/281,041 patent/US20140335178A1/en not_active Abandoned
-
2017
- 2017-03-30 US US15/474,296 patent/US20170202826A1/en not_active Abandoned
-
2020
- 2020-02-25 CY CY20201100172T patent/CY1122685T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012530141A5 (cg-RX-API-DMAC7.html) | ||
| HRP20200297T1 (hr) | Dozni oblici apiksabana | |
| JP2015057451A5 (cg-RX-API-DMAC7.html) | ||
| CL2013000347A1 (es) | Poblacion de microparticulas que comprenden un corticoesteroide clase b incorporado en una matriz formada por un copolimero de acido lactico y acido glicolico, donde dicho corticoesteroide comprende entre 22% a 28% de las microparticulas; preparacion de liberacion controlada; formulacion; y metodo de fabricacion. | |
| EP3682875A3 (en) | Methods of treating pediatric metabolic syndrome | |
| BR112014014262A2 (pt) | nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas. | |
| JP2010222367A5 (cg-RX-API-DMAC7.html) | ||
| CN104812762A8 (en) | Substituted annulated pyrimidines and triazines, and use thereof | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| NZ619857A (en) | A fast dissolving pharmaceutical composition | |
| JP2010518086A5 (cg-RX-API-DMAC7.html) | ||
| AR103981A1 (es) | Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención | |
| AR084865A1 (es) | Preparacion de desintegracion rapida, comprimido dispersable por via oral | |
| JP2014218522A5 (cg-RX-API-DMAC7.html) | ||
| CN110035744A (zh) | 一种尼拉帕尼缓控释药物组合物及其用途 | |
| JP2013503165A5 (cg-RX-API-DMAC7.html) | ||
| CN110062628A (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| NZ602441A (en) | A fast dissolving pharmaceutical composition | |
| JP2016027060A5 (cg-RX-API-DMAC7.html) | ||
| AR083361A1 (es) | Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon | |
| JP2014520871A5 (cg-RX-API-DMAC7.html) | ||
| JP2015510928A5 (cg-RX-API-DMAC7.html) | ||
| JP2015514797A5 (cg-RX-API-DMAC7.html) | ||
| JP2013534527A5 (cg-RX-API-DMAC7.html) | ||
| JP2016535794A5 (ja) | 急速崩壊性固体剤形 |